A Venture Capital firm based in San Francisco, CA, and has an additional office in Japan. The firm is investing from a new fund that closed in 2016. The firm generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 90% of its capital in the USA, Japan and Israel, with the remaining 10% open to global opportunities.
The firm invests in advanced therapeutics, healthcare IT, novel (sensor based IoT) devices and diagnostics, and second-generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. The firm prefers to invest in technologies at an early stage of development.
The firm is interested in working with high quality management teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.
A newly established venture capital firm founded in 2020 and is based in Barcelona, Spain. The firm is currently raising its first fund targeting €30M, and expects to close in mid to late 2021 and become fully operative. The firm is actively seeking investment opportunities and performing due diligence on companies they identify as a fit with the firm. The firm’s focus is in Seed to Series A financings and initial size of investment will be around €500K, and can invest up to €2.5M over the life of investment. While the firm is open to USA-based opportunities, they will focus on those based in Europe, Israel, and Spain where the firm is based.
The firm is exclusively interested in companies in the longevity space. In this regard, the firm is most interested in digital technologies including AI, robotics, data analytics, etc. Traditional therapeutics or devices do not fall within their investment priority, as the firm prefers to seek opportunities that leverage digital technologies to deliver novel therapeutic solutions (i.e. digital therapeutics). The firm is open to very early-stage, pre-revenue technologies and are open to university spin-offs/tech transfers.
The firm is backed by co-founders who have entrepreneurial backgrounds and can be a hands-on investor, assisting with company creation and other support as needed. When investing in companies that are not in geographical proximity to the firm, the firm prefers to co-invest alongside larger VC firms.
If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.
A family office founded in 2009 and based in Toronto, Ontario is now looking to expand into the healthcare sector. The group plans to initially invest approximately $10M into seed-stage deals in the healthcare space and may potentially reserve another pool of capital for additional healthcare investments in the future. The group has flexibility with deal structures and may make either straight equity or convertible loan investments depending on the deal. In addition to capital, the group looks to add value to portfolio companies through marketing and sales expertise. The firm has no specific number of healthcare investments it’s looking to make.
Within healthcare, the group is focused on the medtech, diagnostic and health IT space. The group is particularly interested in newly created or accessible markets such as leveraging smartphones, big data/data mining and AI for healthcare purposes. The group is highly interested in mobile diagnostic devices, diagnostics for the consumer market and portable lab devices. The firm will also look at more traditional FDA regulated medical devices and diagnostics on a secondary basis.
The group seeks companies addressing specific markets, but has no set requirements for entrepreneurs/management teams other than a very focused team that is passionate about the tech and market being pursued. The group typically seeks a board seat along with in an investment, but may not require one depending on the terms of the deal.
If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.
A large designer, developer and manufacturer of drug delivery systems is active in R&D, design and manufacturing in all areas of healthcare. The firm is capable of a variety of deal structures, but prefers to enter into joint ventures and strategic partnerships as the firm seeks to be a value-added investor providing their expertise and capabilities in design and manufacturing as well as the resources of a large company while allowing the entrepreneur to drive the development of the technology.
The firm’s expertise lies in drug delivery devices, but has capabilities and is highly interested in all areas of medical technology/devices, biosensors and wearables, B2B or B2C healthcare IT applications including data analytics and cloud computing as well as robotics and AI as it applies to surgery prosthetics, rehabilitation and drug discovery. The firm has a particular interest in the diabetes space and has done work in this area in the past.
The firm is open to working with all entrepreneurs and is open to companies on a global basis. The firm does look for a board seat along with an investment, but strives to not be restrictive in any way and let the management team run the company.
If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.
Founded in 2014, a venture capital firm specializes in life sciences and medical technology, managing both RMB and USD funds with a total size of $600M. The firm is located in Beijing, China, operated by a professional team with diversified and profound industry backgrounds, having made over 40 investments with high growth potential since 2014. For the firm’s RMB fund, the typical allocation size is 30M-50M RMB, and can go up to 200M RMB. For the USD fund, the firm invests $5M USD on average and can go up to $20M USD.
The firm is open to investing in general Bio-medical industries globally, including diagnostics, medical devices, therapeutics and AI in the healthcare service platform. The firm is especially interested in medical imaging, minimally invasive diagnosis specially IVD and treatment, diagnostic reagents and mobile health. The firm prefers diagnostics companies that are at the growth stage but are looking for biotech companies in the seed stage. It’s not interested in small molecules nor antibodies for now.
The firm prefers companies with China Angle, focusing on promising pioneers that operate in healthcare subsegments with lower regulatory risks and introduce global technology into the Chinese market.
If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
It has been over a year since Life Science Nation (LSN) started organizing virtual conferences, which has been met with overwhelming support from the community of investors, service providers, and early-stage companies within life science and healthcare. Thank you to all who have supported LSN throughout the past year!
LSN is pleased to announce the newest, 3-day Digital RESI conference, June 8-10. Check out the agenda below!
Digital RESI June Agenda
Tuesday June 8
Wednesday June 9
Thursday June 10
10:00am
Corporate Venture Capital The Corporate Landscape Morphed & New Opportunities Abound
Angel Investors Explaining the Process of Engagement
Medtech Strategics Large Medical Device Firms Seeking External Innovation
12:00pm
Innovator’s Pitch Session #1
Innovator’s Pitch Session #3
Innovator’s Pitch Session #5
2:00pm
Impact Investors Life Science Investors Looking for More Than Financial Returns
Family Offices How Do Family Offices View Seed & Series A Rounds?
Big Pharma Pipeline Strategy for Preclinical and Early Clinical Assets
3:00pm
Innovator’s Pitch Session #2
Innovator’s Pitch Session #4
Innovator’s Pitch Session #6
Each panel is held live during the conference and will feature active investors and strategic partners as participants sharing their insights and offering helpful tips to fundraising executives.
Digital RESI June will also feature the Innovator’s Pitch Challenge (IPC) – the virtual pitch experience in which participating companies receive a dedicated webpage accessible via the event live agenda, as well as the opportunity to engage in a live Q&A session with investors and strategic partners interested in their products and services. These sessions provide valuable insights and feedback to help companies improve their skills, as well as build connections in a valuable setting.
Life Science Nation (LSN)’s 4D Meets AI partnering conference successfully concluded last Friday, March 19. Over the two-day event, LSN featured seven exceptional startup companies at the intersection of AI and life science through the Innovator’s Pitch Challenge (IPC).
Each company was featured on a dedicated landing page that hosted their pitch video and supplementary materials, and they participated in a live Q&A session with a panel of investor pitch judges. Conference attendees were able to visit these landing pages or join the live Q&A sessions, and they were encouraged to vote for their favorite IPC companies before the end of the conference.
Many thanks to all the IPC companies for their hard work promoting their technologies and to the pitch judges who supported each session with their feedback. Each company was judged on their supporting materials, as well as their live pitch and Q&A. Congratulations to Huma.AI and Thrive Bioscience for winning their sessions!
Huma.ai is a venture-backed healthcare AI company. It’s ML-enabled, questions and answers-driven knowledge automation platform turns domain experts into their own data scientists so that they can make real-time decisions driven by data. According to its customers, Huma.ai has cracked the Holy Grail.
Thrive is commercializing a family of instruments and software that provide previously unavailable data, imaging, analytics, and automation for cell culture, stem cell culture, and tissue culture for use in biomedical research and cell therapeutics. Thrive has recently started selling the first two instruments in the family, the CellAssist and the CellAssist 50. Both collect 1,000’s of images of live cells in culture, analyzes them, provides guidance and builds a significant database. The CellAssist 50 enables researchers to automatically and remotely image 50 plates of cells on an ongoing basis, generating large amounts of data for live cell biology. Sites include Harvard Stem Cell Institute, Center for Genomic Medicine (Massachusetts General Hospital), Stanford Stem Cell Core, University of Texas Medical Branch, as well as large and small pharma/biotech companies.
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
Next Phase Newsletter 